{"id":"W3172867079","doi":"10.1200/jco.2021.39.15_suppl.1004","title":"Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Toronto; Sunnybrook Health Science Centre","funders":"Roche","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Clinical endpoint; Ven; Fulvestrant; Venetoclax; Oncology; Progression-free survival; Neutropenia; Estrogen receptor; Phases of clinical research; Gastroenterology; Cancer; Breast cancer; Chemotherapy; Randomized controlled trial; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002456211,0.001673775,0.001814399,0.0004853265,0.0003686527,0.001233347,0.001102676,0.00149081,0.008463179],"category_scores_gemma":[0.001665797,0.0006071112,0.00141934,0.000520721,0.00108541,0.0009315507,0.00039961,0.002977422,0.001123609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009044209,"about_ca_system_score_gemma":0.00160229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001158456,"about_ca_topic_score_gemma":0.003235746,"domain_scores_codex":[0.9993304,0.0003954292,0.00002826412,0.00008961014,0.00003901624,0.0001172398],"domain_scores_gemma":[0.9988161,0.0002970147,0.0002003828,0.00008298452,0.0000680519,0.0005354249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9554813,0.01823196,0.0007457837,0.0003869281,0.0006566907,0.00004745553,0.00006286842,0.0005118286,0.00494536,0.0001413431,0.001339058,0.01744933],"study_design_scores_gemma":[0.8678521,0.1277054,0.002207251,0.00002789957,0.0004238905,0.00004471807,0.00002986401,0.0003449998,0.0003698111,0.0001339744,0.0008452956,0.00001484606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9788795,0.003648414,0.0008258897,0.0007159606,0.0005148421,0.007277144,0.002955183,0.0001879903,0.004995094],"genre_scores_gemma":[0.9821614,0.002312896,0.001343612,0.001019687,0.0002553402,0.003955359,0.003437631,0.00004305592,0.005471065],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008463179,"threshold_uncertainty_score":0.02831215,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08351404281916895,"score_gpt":0.4545891997308339,"score_spread":0.371075156911665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}